UY33103A - Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico - Google Patents

Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico

Info

Publication number
UY33103A
UY33103A UY33103A UY33103A UY33103A UY 33103 A UY33103 A UY 33103A UY 33103 A UY33103 A UY 33103A UY 33103 A UY33103 A UY 33103A UY 33103 A UY33103 A UY 33103A
Authority
UY
Uruguay
Prior art keywords
climate
syndrome
suspension
sustained release
pharmaceutical formulation
Prior art date
Application number
UY33103A
Other languages
English (en)
Inventor
Juan Angeles Uribe
Vilboeuf John Claude Savoir
Original Assignee
Techsphere S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44167908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Techsphere S A De C V filed Critical Techsphere S A De C V
Publication of UY33103A publication Critical patent/UY33103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY33103A 2009-12-15 2010-12-13 Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico UY33103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2009013768 2009-12-15

Publications (1)

Publication Number Publication Date
UY33103A true UY33103A (es) 2011-07-29

Family

ID=44167908

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33103A UY33103A (es) 2009-12-15 2010-12-13 Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico

Country Status (34)

Country Link
EP (1) EP2520301B2 (es)
JP (1) JP5900925B2 (es)
KR (1) KR101758407B1 (es)
CN (1) CN102655867B (es)
AR (1) AR079453A1 (es)
AU (1) AU2010330982B2 (es)
BR (1) BR112012013823B1 (es)
CA (1) CA2781999C (es)
CL (1) CL2012001516A1 (es)
CO (1) CO6551723A2 (es)
CY (1) CY1119169T1 (es)
DK (1) DK2520301T4 (es)
EC (1) ECSP12011934A (es)
ES (1) ES2629204T5 (es)
HR (1) HRP20170962T4 (es)
HU (1) HUE035223T2 (es)
IL (1) IL220422A (es)
LT (1) LT2520301T (es)
MA (1) MA33808B1 (es)
MX (1) MX2012006604A (es)
MY (1) MY163619A (es)
NZ (1) NZ600539A (es)
PE (1) PE20130015A1 (es)
PL (1) PL2520301T5 (es)
PT (1) PT2520301T (es)
RS (1) RS56142B2 (es)
RU (1) RU2582272C2 (es)
SG (1) SG181723A1 (es)
SI (2) SI2520301T1 (es)
SM (1) SMT201700318T1 (es)
UA (1) UA108865C2 (es)
UY (1) UY33103A (es)
WO (1) WO2011074931A2 (es)
ZA (1) ZA201203992B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
WO2026015620A1 (en) 2024-07-09 2026-01-15 Farmastar Llc Stable pharmaceutical formulations of progestogens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733407A (en) 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
US4425339A (en) 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US4945103A (en) 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
SE9403389D0 (sv) * 1994-10-06 1994-10-06 Astra Ab Pharmaceutical composition containing derivattves of sex hormones
US5514382A (en) 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
FR2747042B1 (fr) 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
AU1197100A (en) * 1998-10-09 2000-05-01 Pharmacia & Upjohn Company Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
AU5181200A (en) * 1999-06-04 2000-12-28 General Hospital Corporation, The Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7589082B2 (en) * 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico

Also Published As

Publication number Publication date
AR079453A1 (es) 2012-01-25
WO2011074931A2 (es) 2011-06-23
MA33808B1 (fr) 2012-12-03
SMT201700318T1 (it) 2017-09-07
AU2010330982B2 (en) 2015-05-21
EP2520301B2 (en) 2021-03-03
CA2781999C (en) 2018-10-23
HRP20170962T4 (hr) 2021-07-09
CN102655867B (zh) 2015-05-27
UA108865C2 (uk) 2015-06-25
DK2520301T4 (da) 2021-06-07
JP5900925B2 (ja) 2016-04-06
IL220422A (en) 2017-01-31
BR112012013823B1 (pt) 2021-05-25
RU2582272C2 (ru) 2016-04-20
JP2013513658A (ja) 2013-04-22
IL220422A0 (en) 2012-08-30
DK2520301T3 (en) 2017-07-17
EP2520301A2 (en) 2012-11-07
RS56142B1 (sr) 2017-10-31
HRP20170962T1 (hr) 2017-09-22
NZ600539A (en) 2014-10-31
PL2520301T3 (pl) 2017-10-31
RU2012126501A (ru) 2014-01-27
SG181723A1 (en) 2012-07-30
MX2012006604A (es) 2012-08-17
AU2010330982A1 (en) 2012-07-05
CA2781999A1 (en) 2011-06-23
RS56142B2 (sr) 2021-07-30
WO2011074931A3 (es) 2011-09-22
HUE035223T2 (hu) 2018-05-02
PL2520301T5 (pl) 2021-07-05
SI2520301T2 (sl) 2021-08-31
ES2629204T3 (es) 2017-08-07
PT2520301T (pt) 2017-06-30
LT2520301T (lt) 2017-07-25
EP2520301B1 (en) 2017-05-10
HK1170431A1 (en) 2013-03-01
MY163619A (en) 2017-10-13
EP2520301A4 (en) 2013-10-23
KR20120114269A (ko) 2012-10-16
ECSP12011934A (es) 2012-07-31
CL2012001516A1 (es) 2012-12-21
BR112012013823A2 (pt) 2018-07-31
CN102655867A (zh) 2012-09-05
CO6551723A2 (es) 2012-10-31
KR101758407B1 (ko) 2017-07-14
ES2629204T5 (es) 2021-11-02
SI2520301T1 (sl) 2017-07-31
PE20130015A1 (es) 2013-01-30
ZA201203992B (en) 2013-02-27
CY1119169T1 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
ZA201505813B (en) Biologically active molecules, conjugates thereof, and therapeutic uses
ZA201300920B (en) Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL216876A (en) Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells
IL217224B (en) Pyrazolopyrimides, pharmaceutical preparations containing them and their use
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
IL229926A0 (en) 3neil peptides and vaccines containing them
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
EP2435567A4 (en) CDC45L PEPTIDES AND VACCINES CONTAINING THEM
IL220422A0 (en) Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome
BR112014007022A8 (pt) composição farmacêutica, método de melhoria da absorção no intestino delgado e uso de uma composição farmacêutica.
CL2014001167A1 (es) Combinacion que comprende memantina y baclofeno; composicion farmaceutica que la comprende; y uso en el tratamiento del sobrepeso y la obesidad.
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
GB201019971D0 (en) Drug composition and its use in therapy
GB201021425D0 (en) Drug composition and its use in therapy
GB201019972D0 (en) Drug composition and its use in therapy
GB0920267D0 (en) Drug combination and its use in therapy

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20211029